Vaxxinity
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | <1m | <1m | - | - | 6.7m | 15.4m |
| % growth | - | - | (88 %) | - | - | - | 130 % |
| EBITDA | (13.6m) | (37.3m) | (124m) | (73.0m) | (54.0m) | - | - |
| % EBITDA margin | - | (6701 %) | (187824 %) | - | - | - | - |
| Profit | (14.2m) | (40.0m) | (137m) | (75.2m) | (56.9m) | (50.7m) | (58.5m) |
| % profit margin | - | (7174 %) | (207841 %) | - | - | (757 %) | (380 %) |
| EV / revenue | - | - | 8559.1x | - | - | 16.2x | 7.0x |
| EV / EBITDA | - | - | -4.6x | -1.4x | -1.7x | - | - |
| R&D budget | 10.7m | 20.6m | 71.4m | 47.6m | 35.9m | - | - |
| R&D % of revenue | - | 3693 % | 108150 % | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Seed | ||
| N/A | $89.7m | IPO | |
* | $9.3m | Grant | |
| Total Funding | AUD14.4m | ||
Recent News about Vaxxinity
EditVaxxinity is a pioneering biotech company focused on developing innovative biologic medicines to address chronic diseases such as Alzheimer's, Parkinson's, heart disease, migraine, and COVID-19. The company operates in the global healthcare market, aiming to democratize health by making treatments cheaper, safer, more convenient, and effective for all. Vaxxinity's business model revolves around leveraging cutting-edge science and technology to create transformative medicines, which are then brought to market through partnerships and direct sales. The company generates revenue by selling its biologic products to healthcare providers, governments, and other organizations involved in public health. Vaxxinity's team comprises leaders in neurobiology, drug and vaccine development, and infectious disease, all working together to combat human suffering and improve global health outcomes.
Keywords: Biotech, Chronic Diseases, Biologics, Alzheimer's, Parkinson's, Heart Disease, Migraine, COVID-19, Healthcare, Innovation.